Changes in clinical management and diagnosis following DaTscan™ SPECT imaging in patients with clinically uncertain parkinsonian syndromes: A 12-week follow-up study

Neurodegenerative Diseases

Volumn 11, Issue 1, 2012, Pages 22-32

  Kupsch, Andreas ^a   Bajaj, Nin ^c   Weiland, Frederick ^d   Tartaglione, Antonio ^g   Klutmann, Susanne ^b   Copp, Ronald ^e   Sherwin, Paul ^f   Tate, Ann ^f   Grachev, Igor D ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^d SUTTER HEALTH   (United States)

^e i3 Statprobe   (United States)

^f GE HEALTHCARE   (United States)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Clinical management; Clinically uncertain parkinsonian syndrome; DaTscan ; DaTSCAN ; Diagnosis; Ioflupane 123I injection; Parkinsonian syndromes; Parkinsonism; Single photon emission computed tomography

Indexed keywords

IOFLUPANE I 123;

AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SAFETY; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IOFETAMINE; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; QUALITY OF LIFE; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84866422646     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000337351     Document Type: Article

References (34)

1. Kasten M, Chade A, Tanner CM: Epidemiology of Parkinson's disease. Handb Clin Neurol 2007; 83: 129-151.
2. Twelves D, Perkins KS, Counsell C: Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003; 18: 19-31. (Pubitemid 36150204)
3. Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148. (Pubitemid 23054795)
4. Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
5. Spiegel J, Storch A, Jost WH: Early diagnosis of Parkinson's disease. J Neurol 2006; 253:IV/2-IV/7.
6. Schneider SA, Edwards MJ, Mir P, Cordivari C, Hooker J, Dickson J, Quinn N, Bhatia KP: Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007; 22: 2210-2215.
7. Gadoth N: The accuracy of diagnosis of Parkinson's disease. Isr Med Assoc J 2002; 4: 123-124. (Pubitemid 34193046)
8. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R: The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995; 4: 241-248.
9. Meara J, Bhowmick B, Hobson P: Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99-102. (Pubitemid 29161211)
10. Marshall V, Grosset DG: Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003; 18: 1415-1423. (Pubitemid 38035363)
11. Jennings DL, Seiby JP, Oakes D, Eberly S, Murphy J, Marek K: ( 123 I)-CIT and singlephoton emission computed tomography imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004; 61: 1224-1229. (Pubitemid 39062674)
12. Global Parkinson's Disease Survey Steering Committee: Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17: 60-67.
13. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FPCIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15: 503-510. (Pubitemid 30333223)
14. Plotkin M, Amthauer H, Klaffke S, Kühn A, Lüdemann L, Arnold G, Wernecke KD, Kupsch A, Felix R, Venz S: Combined 123IFP- CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005; 112: 677-692. (Pubitemid 40591200)
15. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, Baldessarini RJ, Zea- Ponce Y, Baldwin RM, Innis RB: N-omegafluoroalkyl analogs of (1R)-2 beta-carbomethoxy- 3 beta-(4-iodophenyl)-tropane (beta- CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994; 37: 558-561.
16. Boonij J, Speelman JD, Horstink MW, Wolters EC: The clinical benefit of imaging striatal dopamine transporters with 123I-FPCIT SPECT in differentiating subjects with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266-272.
17. Catafau AM, Tolosa E; DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group: Impact of dopamine transporter SPECT using 123 I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord 2004; 19: 1175-1182. (Pubitemid 39433368)
18. Tolosa E, Borght TV, Moreno E; DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group: accuracy of 123 I-ioflupane (DaTSCAN) in the diagnosis of patients with clinically uncertain parkinsonism: 2-year follow up of an open-label study. Mov Disord 2007; 22: 2346-2351. (Pubitemid 351155979)
19. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
20. Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 67-73. (Pubitemid 30410417)
21. Loøkkegaard A, Werdelin LM, Friberg L: Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 2002; 29: 1623-1629.
22. Bajaj NP, Gontu V, Birchall J, Patterson J, Grosset DG, Lees AJ: Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. J Neurol Neurosurg Psychiatry 2010; 81: 1223-1228.
23. Paulus W, Jellinger K: The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50: 743-755.
24. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG: Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 585-589. (Pubitemid 43844579)
25. Jellinger KA: Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999; 56: 1-29.
26. Rajput AH, Pahwa R, Pahwa P, Rajput A: Prognostic significance of the onset mode in parkinsonism. Neurology 1993; 43: 829-830. (Pubitemid 23121983)
27. Schwingenschuh P, Ruge D, Edwards MJ, Terranova C, Katschnig P, Carrillo F, Silveira- Moriyama L, Schneider SA, Kägi G, Palomar FJ, Talelli P, Dickson J, Lees AJ, Quinn N, Mir P, Rothwell JC, Bhatia KP: Distinguishing SWEDDs patients with asymmetric resting tremor from parkinson's disease: a clinical and electrophysiological study. Mov Disord 2010; 25: 560-569.
28. Van Laere K, Everaert L, Annemans L, Gonce M, Vandenberghe W, Vander Borght T: The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2008; 35: 1367-1376.
29. Hesse S, Oehlwein C, Barthel H, Schwarz J, Polster D, Wagner A, Sabri O: Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm 2006; 113: 1177-1190. (Pubitemid 44291013)
30. Behari M, Srivastava A, Pandey RM: Quality of life in patients with Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 221-226. (Pubitemid 40692833)
31. Hristova DR, Hristov JI, Mateva N, Papathanasiou JV: Quality of life in patients with Parkinson's disease. Folia Med (Plovdiv) 2009; 51: 58-64.
32. Rubenstein LM, DeLeo A, Chrischilles EA: Economic and health-related quality of life considerations of new therapies in parkinson's disease. Pharmacoeconomics 2001; 19: 729-752. (Pubitemid 32664731)
33. Schrag A, Jahanshahi M, Quinn N: How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 1112-1118.
34. Bairactaris C, Demakopoulos N, Tripsianis G, Sioka C, Farmakiotis D, Vadikolias K, Heliopoulos I, Georgoulias P, Tsougos I, Papanastasiou I, Piperidou C: Impact of dopamine transporter single photon emission computed tomography imaging using I-123 ioflupane on diagnoses of patients with parkinsonian syndromes. J Clin Neurosci 2009; 16: 246-252.